200 1- Chinese peptide biochemical co., ltd was established.
In 2004-the company's polypeptide R&D center was rated as "provincial high-tech enterprise R&D center";
2005-The company won the title of "Advanced Enterprise with Foreign Investment" and Export Enterprise of the Year.
2005-The company passed the ISO900 1:2000 quality management system certification.
2006-The company obtained GMP certification from the State Administration of Pharmaceutical Products.
2007-Diagnostic Reagents Department was established.
2008-The company obtained the medical device production license;
2009-The company passed the ISO 13485:2003 quality management system certification and established a postdoctoral workstation;
2009-leuprorelin acetate obtained the new drug certificate and GMP production approval issued by the State Administration of Pharmaceutical Products;
20 10- The company has passed the ISO2700 1:2005 information security certification.
20 10- the company won the title of "Hangzhou technologically advanced service enterprise".
20 10- the company won the title of "Top Ten Service Outsourcing Enterprises in Hangzhou"
20 10- the company's workshop expansion project was completed and the scale was further expanded.
20 10—— By the end of 20 10, the company * * * had obtained 3 invention patents; Accepting 6 invention patents; There are 3 authorized patents for utility models, 2 certificates for new drugs and 2 certificates for medical devices; Undertake 3 provincial and ministerial projects; Won 5 provincial and municipal science and technology awards;
2011-2012-The company passed the FDA inspection twice with zero defects.
20 12- the company broke ground on the new GMP production building.
20 12- Lilly Asia fund becomes the company's strategic investment partner.